Approved clinical antitumor drugs of Kelun pharmaceutical holding subsidiary

[China Pharmaceutical network enterprise news] recently, Sichuan Kelun Pharmaceutical Co., Ltd said that the new structural chemical small molecule anti-tumor drug kl070002 independently developed by its holding subsidiary Sichuan Kelun Botai biomedical Co., Ltd was approved and issued by the State Food and Drug Administration (CFDA) This approval is fast! Application at the beginning of the year, clinical approval in the middle of the year Chemotherapy is still the cornerstone of cancer drug treatment, its efficacy is more accurate, but there are obvious adverse reactions, drug resistance and other problems in the effective dose Kl070002 is a new cytotoxic anti-tumor drug independently developed by the company with independent intellectual property rights The data of non clinical studies showed that the product has a wide anti-tumor spectrum, and is effective for pancreatic cancer, lung cancer, ovarian cancer, gastric cancer, colorectal cancer, liver cancer and other solid tumors; it has a high activity, superior to gemcitabine and capecitabine, and has a significant synergistic effect with sorafenib; it is effective for gemcitabine resistant pancreatic cancer model; It has good tolerance, similar toxicity spectrum with gemcitabine, can be administered orally, and can improve the compliance of patients Kl070002 is expected to provide more drug options for the treatment of high-risk cancer in China, such as lung cancer, colorectal cancer, pancreatic cancer, liver cancer and so on, with great clinical value.